StockNews.AI
TTNP
StockNews.AI
14 days

TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP

1. Titan Pharmaceuticals' merger with KE Sdn. Bhd. is under investigation. 2. Shareholders expected to retain 13.3% ownership post-merger.

2m saved
Insight
Article

FAQ

Why Bearish?

Investigations into mergers often lead to uncertainty and volatility. Historical cases show stock prices may decline during scrutiny.

How important is it?

The ongoing investigation introduces risks that may deter investors and influence stock pricing.

Why Short Term?

The immediate concern surrounding the merger investigation could impact TTNP's stock price.

Related Companies

KEMRNAPFE
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Titan Pharmaceuticals, Inc. (the “Company”) (NasdaqCM: TTNP) and KE Sdn. Bhd. Under the terms of the proposed transaction, shareholders of Titan are expected to own approximately 13.3% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whet.

Related News